Profile Card Research project

Share this record with your favourite social network: Facebook    Delicious    add to CiteUlike
Starting date
September 1, 2003

Duration (months)

Managers or local contacts
Pignatti Pierfranco


CFTR gene mutation screening for CF diagnosis is an imperfect test as not all mutations in CF patients can be determined. In a study on all CF patients born from 1973 to 1981 in the Veneto and Trentino Alto Adige Italian regions, 22/225 alleles carried no identified mutations after a thorough gene analysis performed with efficient molecular genetic screening methods. One of the 113 CF patients had no identified mutation and 20 of them had only one identified allele (Bonizzato et al., 1995). A limited mutation detection rate is observed in other European countries (Estivill et al., 1997). Moreover, of the mutations that can be identified with a thorough mutation screening, only a limited number is represented at reasonable frequencies. In the same paper cited above, only 11/22 mutations identified had a frequency over 1%, and 7/22 were present only once out of 225 alleles screened (Bonizzato et al., 1995). These considerations are of practical use when mutation analysis for CF is considered, as the panel of mutations used includes only the most common mutations in the population, e.g. 16 mutations covering 86.7% of the CF mutation in Veneto and Trentino Alto Adige (Bombieri and Pignatti, 2001). Therefore a need exists for a better CF molecular test. An improved gene analysis method that might help in residual risk determination after a negative mutation analysis could be helpful.
We wish to propose that one of the most common polymorphisms in the CFTR gene, M470V, may be used for this purpose. This polymorphism:
1) turned out to be associated with random CFTR gene mutations of all molecular types in a recent study on non-CF individuals (see next section “preliminary results”). More precisely, the combined frequency of all rare variants among the CFTR genes with the M allele was 3.5 fold that of the CFTR with the V allele (0.260 vs 0.074).
2) in CF patients, the M allele frequency has been reported to be 90% versus 50% in normal alleles, in a study on 200 unrelated normal and mutant CFTR genes (Cuppens et al., 1994). Mutations DF508, G542X, N1303K (Cuppens et al., 1994), W1282X, R117H, R334W, R553X (Dork et al., 1992) are all associated with allele M, while mutation R1162X is not (Dork et al., 1992);
3) also, an increased frequency of the M allele has been reported in CFTR-related diseases: in 146 chronic rhinosinusitis patients, 9/10 patients with a CF mutation had the M allele (Wang et al., 2000); in 12 Chronic Obstructive Pulmonary Disease (COPD) patients M allele frequency was 70.8% versus 35.7 % in 52 controls, and in 19 Disseminated Bronchiectasis (DBE) patients, 5/5 patients carrying CF mutations had the M allele, versus 8/14 (57%) patients not carrying CFTR mutations (Tzetis et al., 2001). In CFTR-related diseases, a wide variety of CFTR gene mutations has been found, therefore no particular mutation panel can be proposed for these diseases, similar to that in use for CF genotyping, and short of complete gene screening, M470V typing could represent a simple first screen method.
On the basis of all these data, we hypothesize that CFTR alleles with the M variant should have an increased risk over CFTR alleles with the V variant of carrying a CF-causing mutation. Therefore, the probability of being a CF at risk couple would increase with the increase of the number of M genes from 0 to 4 in the partners of the couple.
The genotyping for M470V might be useful in: (i) the analysis of CF patients, (ii) atypical CF cases, and (iii) CFTR-related diseases, in particular when no CFTR mutation can be identified with a panel of CF mutations, (iv) as a first, more economic and convenient approach to CF screening countries in which little is yet known on the spectrum of CF causing mutations, or whenever economic and practical considerations suggest a simpler approach involving the typing of only one polymorphism with a simple method instead of a panel of mutations with more complex methods.
In conclusion, we propose to determine the genotype at the M470V polymorphism in families with a CF child, and to compare the results with our previous data on the general population.
If the hypothesis will be verified, modified residual risk calculation tables after mutation analysis, and the inclusion of M470V polymorphism in the CF mutation panels for CF testing, may be proposed.


Fondazione per la Ricerca sulla Fibrosi Cistica - Onlus
Funds: assigned and managed by the department
Syllabus: ENTI.RIC - Finanziamento da enti vari per la ricerca

Project participants

Francesca Belpinati
Technical-administrative staff
Cristina Bombieri
Associate Professor
Giovanni Malerba
Associate Professor
Pierfranco Pignatti

Guido Modiano
Università Roma Tor Vergata
Carlo Castellani
Azienda Ospedaliera Verona
Bianca Maria Ciminelli
Università Roma Tor Vergata
Biology and Genetics Section